The traditional approach to API development has long relied on a fragmented network of partners. One organization supports early process development, another manages scale-up, and yet another handles commercial manufacturing. While this model has been workable, it introduces complexity at every transition point.
A Changing Model for Drug Development
Each handoff carries risk. Each new partner requires alignment, knowledge transfer, and validation. And in an industry where timelines are increasingly compressed, those transitions can become critical points of delay.
As the demands of drug development continue to evolve, sponsors are rethinking this model. The question is no longer whether a partner can deliver at a single stage, but whether they can support the entire journey—from early development through commercial production, without interruption, and without transferring risk back to the client.
The Hidden Cost of Fragmentation
Fragmented development does not just slow timelines. It introduces uncertainty.
When process knowledge is transferred between organizations, subtle details can be lost or misinterpreted. Analytical methods must be revalidated. Manufacturing processes may need to be adjusted to fit new equipment or environments. Even when these transitions are managed carefully, they create opportunities for deviation—and ultimately, for failure.
In traditional models, that risk is often borne by the sponsor. If a tech transfer fails or underperforms, the consequences, delays, added costs, and regulatory complications fall back on the client.
For sponsors, these challenges translate into longer timelines, higher costs, and increased regulatory complexity. In some cases, they can delay critical milestones or require additional studies to ensure consistency.
Integration as a Strategic Advantage
In response, many organizations are moving toward a more integrated approach to API development.
By working with a single partner across the full lifecycle of a program, sponsors can maintain continuity from IND-enabling work through clinical development and into commercial manufacturing. This continuity reduces the need for repeated validation, preserves critical process knowledge, and enables faster, more predictable progression.
More importantly, in a truly integrated model, the risk of technology transfer is not passed between organizations—it is owned and managed within a single partner.
At Olon USA, this distinction is intentional and central to the value proposition. The responsibility for successful tech transfer, from development through scale-up and into commercial production, sits with Olon, not the client. That shift materially reduces sponsor risk and removes one of the most common points of failure in the development lifecycle.
An integrated model also allows for earlier alignment between development and manufacturing teams. Decisions made during process development can be informed by commercial considerations, helping to avoid costly adjustments later in the program.
Bridging Global Scale with Local Execution
For many sponsors, integration must also extend beyond a single location.
Global development programs require both scale and flexibility. They demand access to advanced capabilities, diverse expertise, and the ability to support regulatory requirements across multiple regions. At the same time, there is increasing value in having strong local execution, particularly within the United States.
Olon USA offers a model that bridges these needs. By combining U.S.-based manufacturing capabilities with the broader strength of a global network, the organization provides sponsors with both localized control and international scalability. This approach allows companies to maintain consistency across their programs while adapting to the specific demands of each phase, without introducing new transfer risks at each step.
Designed for Speed, Built for Reliability
In today’s environment, speed is not achieved by cutting corners—it is achieved by eliminating unnecessary complexity and risk.
An integrated development model reduces the friction that typically slows programs down. It enables faster decision-making, clearer communication, and more efficient execution. At the same time, it strengthens reliability by ensuring that the same team remains accountable throughout the lifecycle of the project, including full ownership of tech transfer success.
For sponsors navigating increasingly competitive timelines, this combination of speed, accountability, and risk mitigation is critical.
A Smarter Path Forward
As the industry moves further into 2026, the expectations placed on API partners are changing. Sponsors are no longer looking for isolated capabilities. They are seeking partners who can deliver continuity, alignment, and, critically, take ownership of the risks that have historically sat with the client.
Olon USA works with pharmaceutical and biotech companies to provide fully integrated API development and manufacturing solutions, supporting programs from early development through commercial production. By simplifying the path forward and by owning the risk of tech transfer, the organization helps sponsors reduce uncertainty, accelerate timelines, and bring therapies to market with greater confidence.